Orange Book product · Brand (NDA)
TRANSDERM SCOP
SCOPOLAMINE
At a glance
Approved Prior to Jan 1, 1982
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
No patent or exclusivity dates are listed for this product.
Pharmaceutical detail
Active ingredient
SCOPOLAMINE
Strength
1MG/72HR
Dosage form
SYSTEM
Route
TRANSDERMAL
TE code
AB
Application
NDA 017874
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2025SCOPOLAMINEGeneric (ANDA)
ANDA 218384 · AMNEAL
- 2024SCOPOLAMINEGeneric (ANDA)
ANDA 217893 · ZYDUS PHARMS
- 2024SCOPOLAMINEGeneric (ANDA)
ANDA 215329 · RHODES PHARMS
- 2022SCOPOLAMINEGeneric (ANDA)
ANDA 208769 · ACTAVIS LABS UT INC
- 2020SCOPOLAMINEGeneric (ANDA)
ANDA 212342 · RICONPHARMA LLC
- 2019SCOPOLAMINEGeneric (ANDA)
ANDA 203753 · MYLAN TECHNOLOGIES
- 2015SCOPOLAMINEGeneric (ANDA)
ANDA 078830 · PADAGIS US
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
